Clifford Chance advised Société Générale and KBC Securities on the successful initial public offering of Inventiva and its listing on Euronext Paris on 14 February 2017.

Inventiva is a biopharmaceutical company developing innovative therapies, particularly to treat fibrosis, and the IPO valued the Company at €133 million.

The IPO proceeds (€48 million) are intended to allow the pursuit of the clinical development of IVA337 program for the treatment of NASH and SSc until the end of the clinical studies of phase IIb, and to pursue the clinical development of IVA336 for MPS. The balance are intended to be used to pursue the development of the Company’s preclinical portfolio, particularly the Yap-Tead program.

Clifford Chance advised Société Générale and KBC Securities on US law, led by Alex Bafi, partner and Olivier Plessis, senior associate.